Liquidia Corporation Announces $100 Million in New
Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from...
Source: globenewswire.com
📰 Functional Class News
Page 2 - Functional Class News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Functional Class. Real-time updates on events, politics, business and more.
Liquidia Corporation Announces $100 Million in New Financings
Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from HealthCare Royalty under current financing...
Source: marketscreener.com
Liquidia Corporation Announces $100 Million in New Financings - Liquidia (NASDAQ:LQDA)
Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from HealthCare Royalty under current financing agreement
Source: benzinga.com
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 ('793 Patent) - Liquidia (NASDAQ:LQDA)
Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalationLiquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. 20, 2023
Source: benzinga.com
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 ('793 Patent) -December 20, 2023 at 04:57 pm EST
Liquidia will pursue final FDA approval for YUTREPIA™ inhalationLiquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. 20, 2023 ...
Source: marketscreener.com
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)--Nov 9, 2023--
Source: bdtonline.com
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024Hired sales force in preparation of potential...
United States Jason Adair Pharmosa Biopharm Roger Jeffs Liquidia Technologies Inc United Therapeutics Corporation
Source: marketscreener.com
Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves
New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip, an investigational device in the US
Source: dicardiology.com
Abbott reports positive TriClip, MitraClip data
Abbott (NYSE: ABT) announced positive data for two of its minimally invasive heart devices for treating mitral and tricuspid valve disease.
San Francisco United States David Adams Michael Dale Mount Sinai Health System Icahn School Of Medicine At Mount Sinai
Source: massdevice.com
Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves
New data presented at Transcatheter Cardiovascular Therapeutics 2023 from the TRILUMINATE™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid...
Michael Dale David Adams Mount Sinai Health System York Heart Association Icahn School Of Medicine At Mount Sinai Cardiovascular Research Foundation
Source: marketscreener.com